Neuer Therapieansatz bei refraktärer CLL Arzerra® (Ofatumumab): Neuartiger CD20-Antikörper jetzt zugelassen | Zendy

AI Assistant Blog Pricing

Open Access

Neuer Therapieansatz bei refraktärer CLL Arzerra® (Ofatumumab): Neuartiger CD20-Antikörper jetzt zugelassen

Publication year - 2010

Publication title -

onkologie

Language(s) - German

Resource type - Journals

eISSN - 1423-0240

pISSN - 0378-584X

DOI - 10.1159/000318203

Subject(s) - ofatumumab , medicine , cd20 , lymphoma

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Empowering knowledge with every search

About

About Careers Publisher Partners Contact Us

Learn

FAQs Blog Terms of Use Privacy Policy

Discover

Explore

Copyright Knowledge E © 2025. All Rights Reserved.